ALT	Alanine Aminotransferase
ASCVD	Atherosclerotic Cardiovascular Disease
AST	Aspartate Aminotransferase
CK	Creatine Kinase
CKD	Chronic Kidney Disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CV	Cardiovascular
CVD	Cardiovascular Disease
DIAL	Diabetes Lifetime-Perspective Prediction Model
DM	Diabetes Mellitus
EAS	European Atherosclerosis Society
eGFR	Estimated Glomerular Filtration Rate
ESC	European Society of Cardiology
HDL-C	High-Density Lipoprotein Cholesterol
LDL-C	Low-Density Lipoprotein Cholesterol
LIFE-CVD	Lifetime Cardiovascular Disease Risk Model
LLT	Lipid-Lowering Therapy
non-HDL-C	Non-High-Density Lipoprotein Cholesterol
OR	Odds Ratio
PCSK9	Proprotein Convertase Subtilisin/Kexin Type 9
PCSK9i	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
PREVENT	Predicting Risk of Cardiovascular Disease Events Model
SCORE2	Systematic Coronary Risk Evaluation 2
SMART	Secondary Manifestations of Arterial Disease Risk Score
SMART-REACH	SMART Risk Reduction and Extension of Life Expectancy Model
SD	Standard Deviation
T0	Baseline Assessment
T1	Short-Term Follow-Up (6–12 Weeks)
T2	Long-Term Follow-Up (≥1 Year)